Company Profile

Axios Biosciences
Profile last edited on: 6/23/2015      CAGE: 5M0T7      UEI: ZSHNXQNE5DN1

Business Identifier: Next generation of oncology drugs
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

213 Harvard Street 3r
Cambridge, MA 02139
   (617) 750-0330
Location: Single
Congr. District: 07
County: Middlesex

Public Profile

Axios Biosciences is revolutionizing oncology drug discovery by identifying drugs active in the tumor microenvironment where tumors interact with non-malignant tissue and can dramatically affect drug sensitivity. The firm is using unique technologies, including one published in the journal Nature Medicine, to identify promising compounds for primary or metastatic cancers in the bone.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 1 NIH $288,695
Project Title: Probes Targeting Multiple Myeloma in the Context of Tumor-Stromal Interactions

Key People / Management

  Ashraf Haque -- Founder / Advisory Board Member

  Douglas Mcmillin -- Founder

  Charlie Popkin -- Cfo

Company News

There are no news available.